Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?

ConclusionsWe highly recommend considering JCPyV-DNA detection and NCCR re-organizations as viral biomarkers in order to accurately identify JCPyV-infected patients with a specific humoral response not yet detectable and to identify NCCR arrangements correlated with the onset of neurovirulent variants.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research